ASLAN Pharmaceuticals "announced that it has entered into a definitive purchase agreement to raise gross proceeds of approximately $20 million resulting from the sale of its ordinary shares and accompanying purchase warrants, at a purchase price of $0.178 per ordinary share to BVF Partners L.P., K2 HealthVentures and certain existing investors. In addition, ASLAN will have the potential to receive up to an additional $80 million if all purchase warrants being issued in connection with the Purchase Agreement are fully exercised."
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on ASLN:
- ASLAN Pharmaceuticals Announces Completion of Recruitment in Phase 2b TREK-AD Study of Eblasakimab in Atopic Dermatitis Patients
- ASLAN Pharmaceuticals Announces $20M Private Placement Led by BVF Partners L.P. With the Potential to Receive Up to an Additional $80M
- Aslan, Thermo Fisher announce partnership for manufacturing eblasakimab